<DOC>
	<DOCNO>NCT01594125</DOCNO>
	<brief_summary>The aim study investigate safety , tolerability , efficacy pharmacokinetics ( PK ) Japanese hepatocellular carcinoma amenable curative surgery loco regional therapy</brief_summary>
	<brief_title>Dose Escalation Study Nintedanib ( BIBF 1120 ) Japanese Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically/cytologically confirm hepatocellular carcinoma amenable curative surgery locoregional therapy 2 . Age 20 year old 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) score 0 1 4 . ChildPugh score 7 less 5 . Life expectancy 3 month 6 . Time interval last locoregional therapy 4 week 7 . Written inform consent accordance good clinical practice ( GCP ) Exclusion criterion : 1 . More one line prior systemic therapy metastatic/unresectable hepatocellular carcinoma ( HCC ) 2 . Fibrolamellar HCC 3 . Uncontrolled refractory ascites 4 . Inadequate organ function 5 . Variceal bleed within 6 month presence inappropriate varix 6 . History major thrombotic ( except portal vein thrombosis ) clinically relevant major bleed event past 6 month 7 . Major surgery within 4 week 8 . Known inherited predisposition bleed thrombosis 9 . Significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>